(Total Views: 533)
Posted On: 08/27/2024 8:43:33 PM
Post# of 155303
Re: sherlock57 #146023
"What about combining leronlimab with a LAG-3 inhibitor?"
Investors Hangout: https://investorshangout.com/post/view?id=671...9Ye0"
Leronlimab may already deal with this checkpoint by down regulating JAK2, STAT3, and IL-6 (via CCR5). Our clinicals, so far, are showing that Leronlimab helps the immune system regain control of the microenvironment from the cancer. So far, it looks like Leronlimab takes back the immune system from the disregulation caused by foreign trauma (cancer, viral infection, etc) better than checkpoint inhibitors. Additionally, it seems to do this without the black box side effects that comes with most checkpoint inhibitors. Most checkpoint inhibitors seem to just add to the disregulation of the rest of the immune system, either through suppression of the rest of the system, or the toxic chemistry of the drug exiting through the liver and kidneys.
"Studies on the interaction mechanisms between LAG3 and FGL1 in HCC showed that oxysophocarpine promotes the therapeutic effect of the anti-LAG3 mAb by inhibiting the expression of its ligand FGL1 via blocking the IL-6 related JAK2/STAT3 signal pathway (46)."
https://www.frontiersin.org/journals/immunolo...85091/full
Investors Hangout: https://investorshangout.com/post/view?id=671...9Ye0"
Leronlimab may already deal with this checkpoint by down regulating JAK2, STAT3, and IL-6 (via CCR5). Our clinicals, so far, are showing that Leronlimab helps the immune system regain control of the microenvironment from the cancer. So far, it looks like Leronlimab takes back the immune system from the disregulation caused by foreign trauma (cancer, viral infection, etc) better than checkpoint inhibitors. Additionally, it seems to do this without the black box side effects that comes with most checkpoint inhibitors. Most checkpoint inhibitors seem to just add to the disregulation of the rest of the immune system, either through suppression of the rest of the system, or the toxic chemistry of the drug exiting through the liver and kidneys.
"Studies on the interaction mechanisms between LAG3 and FGL1 in HCC showed that oxysophocarpine promotes the therapeutic effect of the anti-LAG3 mAb by inhibiting the expression of its ligand FGL1 via blocking the IL-6 related JAK2/STAT3 signal pathway (46)."
https://www.frontiersin.org/journals/immunolo...85091/full
(7)
(0)
